diethyl (4-chlorobutyl)malonate | 18719-44-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethyl (4-chlorobutyl)malonate
• 英文别名: diethyl 2-(4-chlorobutyl)malonate；ω-Chlorbutylmalonsaeurediethylester；(4-chloro-butyl)-malonic acid diethyl ester；(4-Chlor-butyl)-malonsaeure-diaethylester；diethyl 2-(4-chlorobutyl)propanedioate
• CAS: 18719-44-3
• 化学式: C₁₁H₁₉ClO₄
• 分子量: 250.722
• InChiKey: LULFMPCFMFPELT-UHFFFAOYSA-N

物化性质

• 沸点：
  145-148 °C(Press: 10 Torr)
• 密度：
  1.095±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diethyl (4-chlorobutyl)malonate 在 氯仿 、 溴 、 碘 作用下， 生成 bromo-(4-chloro-butyl)-malonic acid diethyl ester
  参考文献：
  名称：

  Sayles; Degering, Journal of the American Chemical Society, 1949, vol. 71, p. 3162

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴-4-氯丁烷 、 丙二酸二乙酯 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以87.5%的产率得到diethyl (4-chlorobutyl)malonate
  参考文献：
  名称：

  惰性烷基氯的光氧化还原活化与芳香烯烃的还原交叉偶联

  摘要：

  介绍了惰性氯代烷烃与烯烃交叉偶联反应的光氧化还原活化，在温和条件下具有广泛的官能团耐受性。通过结合 UV/Vis 光谱、EPR、自由基钟和氘标记实验，[Ni(Py 2 Ts tacn)] +被认为具有催化活性来激活 Csp 3 -Cl 键，形成自由基，与烯烃。

  DOI：

  10.1002/anie.202114365

文献信息

• Heterocyclic compounds
  申请人：——

  公开号：US20030166697A1

  公开（公告）日：2003-09-04

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R 1 -Het-D-E  [1] wherein: R 1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种用于高脂血症的预防或治疗剂，其活性成分为式[1]所示的杂环化合物或其药学上可接受的盐：R1-Het-D-E [1]其中：R1为任选取代的芳基或芳香性杂环基团，Het为二价芳香性杂环基团，D为亚烷基、亚烯基、亚炔基等，E为羧基等，以及上述式[1]所示杂环化合物中的新型化合物，其具有降低血液甘油三酯、降低LDL-C、降低血糖、降低血液胰岛素、增加HDL-C或降低动脉粥样硬化指数的效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖等疾病。
• Intramolecular reactions. Part VI. Rates of ring formation in reactions of ω-halogenoalkylmalonic esters with bases
  作者：A. C. Knipe、C. J. M. Stirling

  DOI：10.1039/j29680000067

  日期：——

  Reactions of ω-halogenoalkylmalonic esters, X·[CH2]n·CH(CO2Et)2(X = Cl or Br; n= 2,3,4, or 5), with potassium t-butoxide in t-butyl alcohol and with sodium ethoxide in ethanol have been investigated. In both solvent systems and with each ester studied, the sole product is the cycloalkane-1,1-dicarboxylate which results from intramolecular nucleophilic substitution. In reactions with t-butoxide, the

  ω-卤代烷基丙二酸酯X·[CH 2 ] n ·CH（CO 2 Et）2（X = Cl或Br; n= 2,3,4或5），已研究了叔丁醇钾在叔丁醇中的乙醇钠与乙醇钠的乙醇溶液。在两种溶剂体系中以及研究的每种酯中，唯一的产物是由分子内亲核取代产生的环烷-1,1-二羧酸酯。在与叔丁醇的反应中，三元，四元，五元和六元环的相对闭合速率为650,000：1：6500：5，动力学表明卤代酯已转化为碳负离子随后在速率确定步骤中环化。在环形成动力学的其他数据背景下，以共轭控制环闭合的方式讨论了结果。二乙基环烷-1 在无环酯为惰性的条件下，在叔丁醇中用叔丁醇钾处理1-二羧酸酯进行酯交换反应。酯交换反应的速率与环的大小成反比，并且基于环从三到五个扩环而引起的反应位点空间干扰的增加来解释该观察结果。
• Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists
  作者：Tetsuo Asaki、Tomiyoshi Aoki、Taisuke Hamamoto、Yukiteru Sugiyama、Shinji Ohmachi、Kenji Kuwabara、Kohji Murakami、Makoto Todo

  DOI：10.1016/j.bmc.2007.10.007

  日期：2008.1

  A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPAR alpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPAR alpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPAR alpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPAR alpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes. (C) 2007 Elsevier Ltd. All rights reserved.
• Ring-closure reactions. 22. Kinetics of cyclization of diethyl (.omega.-bromoalkyl)malonates in the range of 4- to 21-membered rings. Role of ring strain
  作者：Maria Antonietta Casadei、Carlo Galli、Luigi Mandolini

  DOI：10.1021/ja00316a039

  日期：1984.2
• Crystal of heterocyclic compound
  申请人：Okadai Takeshi

  公开号：US20070027198A1

  公开（公告）日：2007-02-01

  The main purpose of the invention is to provide a new specific crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid. The invention includes, for example, a crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid, which has peaks at the angles of diffraction of at least 12.4°, 17.1°, and 20.8° in a powder X-ray diffraction spectrum, and a preventive or therapeutic agent comprising the crystal as an active ingredient for use in coronary artery diseases, cerebral infarction, hyperlipemia, arteriosclerosis, diabetes mellitus, hypertension, or obesity.